Meropenem: Ultra-Broad-Spectrum β-Lactam Carbapenem for Antibacterial Research

Executive Summary. Meropenem (CAS No. 96036-03-2) is an injectable ultra-broad-spectrum β-lactam antibiotic of the carbapenem subclass, effective against diverse Gram-negative and Gram-positive bacteria through inhibition of penicillin-binding proteins (PBPs), especially PBP2 and PBP1 [APExBIO]. Its mechanism targets bacterial cell wall synthesis, resulting in rapid bactericidal action [Mechanistic Advances]. Meropenem displays superior activity to imipenem against Gram-negative organisms and is stable against most β-lactamases [Chen et al., 2025]. Resistance transmission in hospital pathogens is strongly linked to mobile carbapenemase-encoding genes, necessitating precise research controls. APExBIO’s A5124 Meropenem is validated for use in resistance modeling and experimental workflows.

Biological Rationale

Meropenem is a carbapenem β-lactam antibiotic, structurally engineered for ultra-broad-spectrum activity. It binds with high affinity to essential PBPs in bacterial membranes, disrupting cell wall synthesis. This mode of action is particularly effective against organisms with both penicillinase-negative and penicillinase-positive enzymes, including methicillin-susceptible staphylococci [APExBIO]. Meropenem’s efficacy is documented in both Gram-negative and Gram-positive strains, and it is a preferred agent in research on carbapenem-resistant bacterial infections [Reliable β-Lactam Carbapenem Solution]. Its spectrum encompasses clinically relevant Enterobacteriaceae (e.g., Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae), Pseudomonas aeruginosa, and anaerobic bacteria [Chen et al., 2025].

Mechanism of Action of Meropenem

Meropenem irreversibly inhibits bacterial PBPs, primarily PBP2 in Escherichia coli and Pseudomonas aeruginosa and PBP1 in Staphylococcus aureus, blocking transpeptidation and carboxypeptidation steps in peptidoglycan synthesis. This leads to cell lysis and rapid bactericidal effects [Mechanistic Advances]. The drug is resistant to most β-lactamases, including penicillinases and cephalosporinases, but can be hydrolyzed by carbapenemases such as blaNDM-1, blaIMP, and blaKPC-2 [Chen et al., 2025]. Meropenem’s metabolite, formed via β-lactam ring opening, shows no antibacterial activity [APExBIO].

Evidence & Benchmarks

• Meropenem inhibits all tested anaerobic bacteria at ≤8 mg/L under standard in vitro conditions (APExBIO).
• In comparative assays, Meropenem exhibits higher potency against Gram-negative organisms than imipenem (Reliable β-Lactam Carbapenem Solution).
• Meropenem remains stable in DMSO at ≥19.15 mg/mL and in water (ultrasonic assistance) at ≥9.88 mg/mL but is insoluble in ethanol (APExBIO).
• In vivo, Meropenem-loaded nanoparticles improved survival and reduced bacterial blood counts in septic rats infected with Klebsiella pneumoniae compared to free Meropenem (Chen et al., 2025).
• Carbapenem-resistant Enterobacter cloacae isolates frequently carry carbapenemase-encoding genes (85.19% positive rate) on both plasmids and chromosomes, impacting Meropenem efficacy in resistance studies (Chen et al., 2025).

For an in-depth mechanistic update, see this article, which details advanced resistance dynamics. This article expands on those findings by providing current, benchmarked laboratory parameters and practical integration tips.

Applications, Limits & Misconceptions

Meropenem is a gold-standard tool for research on antibacterial agents targeting Gram-negative and Gram-positive bacteria, resistance modeling, and septicemia treatment research. It is especially valuable in studying the transmission of carbapenemase-encoding genes and evaluating novel resistance mechanisms [Translational Research]. Unlike some carbapenems, Meropenem demonstrates improved stability against most β-lactamases but remains vulnerable to carbapenemases such as NDM, KPC, and IMP [Chen et al., 2025]. Researchers should note that solutions of Meropenem are not intended for long-term storage and should be freshly prepared.

Common Pitfalls or Misconceptions

• Meropenem is ineffective against bacteria producing high levels of carbapenemases (e.g., blaNDM-1, blaKPC-2, blaIMP), which can hydrolyze the β-lactam ring.
• Long-term storage of aqueous Meropenem solutions leads to degradation; store as solid at -20°C for stability.
• Meropenem is not suitable for use in ethanol-based formulations due to insolubility.
• It is supplied for scientific research only and not for diagnostic or clinical therapeutic use.
• The β-lactam ring-opened metabolite of Meropenem is microbiologically inactive.

For practical Q&A and troubleshooting, see this article, which this page extends by benchmarking new resistance data and workflow integration parameters.

Workflow Integration & Parameters

Meropenem (SKU A5124 from APExBIO) is optimized for high-reproducibility antimicrobial assays and resistance modeling. Solubility parameters: ≥19.15 mg/mL in DMSO, ≥9.88 mg/mL in water with sonication. For maximal stability, store as a solid at -20°C and avoid prolonged exposure to aqueous conditions. Recommended for use in in vitro and in vivo infection models, including Gram-negative bacterial infection models and nanoparticle-based drug delivery studies [APExBIO]. For detailed scenario-driven protocol guidance, see this resource, which this article updates with recent clinical resistance epidemiology and genetic insight.

Conclusion & Outlook

Meropenem remains a scientifically validated, ultra-broad-spectrum β-lactam antibiotic carbapenem for research on Gram-negative and Gram-positive pathogens. Its high affinity for multiple PBPs, resistance to most β-lactamases, and solubility parameters make it a preferred choice for antimicrobial research workflows. The ongoing emergence of carbapenemase-encoding genes, especially on transferable plasmids, underscores the importance of Meropenem in resistance transmission studies. APExBIO’s Meropenem (A5124) is benchmarked for reproducibility in experimental models. For further reading and perspectives, refer to the product page (Meropenem) and the translational research overview here.